Voyager Therapeutics (VYGR) Total Non-Current Liabilities (2014 - 2024)

Voyager Therapeutics has reported Total Non-Current Liabilities for 11 years, with the latest figure at $56.4 million in Q3 2024.

• Quarterly Total Non-Current Liabilities fell 43.36% year-over-year to $56.4 million in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $56.4 million (down 43.36% YoY) and the FY2023 annual result came in at $96.9 million, up 22.55% from the prior year.
• Total Non-Current Liabilities retreated to $56.4 million in Q3 2024 per VYGR's latest filing, from $59.6 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $211.8 million in Q1 2020 and troughed at $56.3 million in Q3 2021.
• A 5-year average of $91.5 million and a median of $80.6 million in 2022 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2021 and 2022: Total Non-Current Liabilities sank 72.44% in 2021, then surged 88.68% in 2022.
• Over 5 years, Total Non-Current Liabilities stood at $62.9 million in 2020, then slipped by 5.83% to $59.2 million in 2021, then jumped by 33.54% to $79.0 million in 2022, then advanced by 22.55% to $96.9 million in 2023, then sank by 41.81% to $56.4 million in 2024.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $56.4 million, $59.6 million, and $85.7 million for Q3 2024, Q2 2024, and Q1 2024 respectively.